ストックスクリーナーアプリを入手
3.715
2.91%
0.105
アフターアワーズ：
3.89
0.175
+4.71%
Sagimet Biosciences Inc (SGMT) 最新ニュース
Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In? - Insider Monkey
10 Best Get Rich Quick Stocks To Invest In - Insider Monkey
Brokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $23.00 - Defense World
10 Hot Penny Stocks to Buy Now - Insider Monkey
Unveiling Hidden Gems: The Hot Penny Stock You Might Be Missing - Reporteros del Sur -
Sagimet Biosciences Inc. (SGMT): Among the Hot Penny Stocks to Buy Now - Insider Monkey
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Sagimet Biosciences Announces Oral Presentation at the MASH - GlobeNewswire
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic ... - The Bakersfield Californian
Could This New MASH Drug Transform Liver Disease Treatment? Key Phase 2b Results Revealed - StockTitan
FY2024 Earnings Estimate for SGMT Issued By Leerink Partnrs - MarketBeat
Technical analysis of Sagimet Biosciences Inc (SGMT) stock chart patterns - US Post News
FY2024 Earnings Forecast for SGMT Issued By Leerink Partnrs - Defense World
Keeping an Eye on Sagimet Biosciences Inc (SGMT) After Insider Trading Activity - Knox Daily
Sagimet Biosciences Inc (NASDAQ:SGMT) Up 47.7% Since 52-Week Low; YTD Rose 1.56% – Here’s What You Need To Do – Marketing Sentinel - Marketing Sentinel
Equities Analysts Issue Forecasts for SGMT FY2029 Earnings - MarketBeat
Prepare Yourself for Liftoff: Sagimet Biosciences Inc (SGMT) - SETE News
Sagimet Biosciences Inc (SGMT)’s results reveal risk - US Post News
Analytical Overview: Sagimet Biosciences Inc (SGMT)’s Ratios Tell a Financial Story - The Dwinnex
US Penny Stocks Spotlight: Gevo And 2 Other Promising Picks - Yahoo Finance
Buy Recommendation for Sagimet Biosciences: Denifanstat’s Unique Profile and Undervaluation Offer Compelling Investment Opportunity - TipRanks
What's Going On With Sagimet Biosciences Stock On Thursday? - MSN
JPMorgan Chase & Co. Boosts Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Sagimet Stock Soars To 10-Month High, Retail’s Fired Up Over Presentation On Lead MASH Drug Candidate - MSN
Barclays PLC Has $159,000 Stock Position in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
With 43% stake, Sagimet Biosciences Inc. (NASDAQ:SGMT) seems to have captured institutional investors' interest - Simply Wall St
Sagimet Biosciences' SWOT analysis: promising NASH drug faces funding hurdles - Investing.com
Geode Capital Management LLC Acquires 91,246 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
When (SGMT) Moves Investors should Listen - Stock Traders Daily
Gaining Ground: Sagimet Biosciences Inc (SGMT) Closes Lower at 5.37, Down -3.59 - The Dwinnex
Barclays PLC Boosts Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference - The Manila Times
Sagimet to Present Breakthrough MASH Treatment Data at MASH-TAG Conference 2025 - StockTitan
Sagimet Biosciences Updates Investor Presentation in Recent 8-K Filing - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $23.00 Average PT from Analysts - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
(SGMT) Trading Advice - Stock Traders Daily
Sagimet Biosciences: A Rising Star in the Fight Against NASH with Promising Clinical Data for Denifanstat - mediahousepress
0.22%
0.81%
大文字化:
|
ボリューム (24 時間):